This is a randomized phase II trial including 40 patients with castration resistant
metastatic cancer prostate (CRMPC).
Patients will be randomized between treatment with a dendritic cell vaccine plus docetaxel
and docetaxel alone.
The primary objective is to evaluate the vaccine specific immune response and patients will
be evlauated with blood tests and DTH reactions during the treatment course.
Secondary objectives are to evaluate clinical response by objective response
(RECIST-criteria, 18F-NaF-PET/CT scan), PSA response, pain response and finally we determine
time to progression and overall survival.